Science

Our Science

HOME

>

Science

>

Our Science

Placing the creation of new drug candidate
compounds at the centre of our R&D.

Advalife Science views life as a complex system of interconnected relationships. Linking basic research, drug discovery and clinical insight, we pursue the discovery, evaluation and development of new drug candidates.


Research & Development

The centre of our R&D

New drug candidates are the main axis of our research and development. Rather than confining ourselves to a single-component, single-target framework, we pursue the discovery and scientific validation of candidates from a complex-systems standpoint that takes in multiple components, multiple targets and network effects.

Advalife Science research and development structure: new drug candidates at the centre, with two research areas — Biologics Candidates, the primary area, and Endogenous Biogenic Nanoparticles Candidate Products.Advalife Science research and development structure: new drug candidates at the centre, with two research areas — Biologics Candidates, the primary area, and Endogenous Biogenic Nanoparticles Candidate Products.
  • Our R&D policy: rather than starting from any one research subject, we position each research area beneath a single overriding objective — the creation of new drug candidates.


Our Approach

We do not reject reductionist analysis; we take in its results while treating the interactions among molecules, cells, tissues and the whole organism as a system. Research hypotheses are formed on scientific evidence and connected through to candidate evaluation, intellectual property, joint research, non-clinical work, manufacturing and CMC, and clinical development.

01

Clinical insight and open questions

Complex-systems drug discovery: the research base / Taking multi-layered, multi-factor interactions as a whole.

trending_flatarrow_downward

02

Hypothesis formation

Capturing the relationships between multiple factors and turning them into testable hypotheses.

trending_flatarrow_downward

03

Basic and non-clinical research

Validating activity, quality and safety step by step.

arrow_downward

06

Clinical development

Bridging to drug development in line with regulatory requirements.

keyboard_backspacearrow_downward

05

Intellectual property and joint research

Protecting results as intellectual property and extending them into collaborations with universities and companies.

keyboard_backspacearrow_downward

04

Evaluation of candidate compounds

Narrowing down candidates on the basis of reproducibility and developability.

Research → Drug Discovery → CMC → Clinical Development

Research results are carried step by step through candidate evaluation, non-clinical work, manufacturing and CMC, and clinical development.


Scientific Framework

Research and Development Philosophy and Guiding Principles

Research and Development Philosophy and Guiding Principles, cover page

A document setting out Advalife Science's research and development philosophy, the principles that guide scientific judgement, and its approach to translation from research into medicine development. It presents the view of life as a complex system, the handling of research hypotheses and evidence, scientific validation and reproducibility, and the principles that connect intellectual property, non-clinical research, manufacturing, CMC and clinical development.

Read the Research and Development Philosophy

English · 21 pages · online viewing


Research Platform

We build the research, manufacturing, quality and development platform needed to move development of new drugs forward, and carry our research results through to the next stage.

Discovery and evaluation

Through joint research with universities and research institutions, we examine mechanism of action, relevance to disease and assay systems from several angles.

Manufacturing and quality

With manufacturing and quality control in view from the research stage, we build evaluation and manufacturing platforms that give reproducible results.

Development and translation

By connecting non-clinical and clinical development, intellectual property, CRO and pharmaceutical functions, we work towards the transition into drug development.

To support research activity with research institutions and companies in Japan and abroad, we maintain a supply capability for research materials through a group company.

Research

Basic and joint research

Manufacturing

Manufacturing and quality

CRO

Studies and development support

Pharma

Drug development


Collaboration

Joint research and academic partnerships

Working with universities, research institutions, healthcare institutions and pharmaceutical organisations in Japan and abroad, we connect research results through to the development of new drug candidate. We do not place any single disease area at the centre of the organisation as a whole; our research runs across multiple biological phenomena and disease areas.


Universities and research institutions

Kyoto University

Kyushu University

Tokushima University

Osaka International Cancer Institute

University of Hyogo

Osaka Metropolitan University

The content and scope of each collaboration differ by institution and by research theme.
Research subjects and candidates are not an indication of efficacy or safety as approved pharmaceutical products.
The information published here is updated as appropriate in the light of research progress, intellectual property, joint research agreements, and applicable laws and regulations.

For details of each collaboration, funded research project and endowed course, please see


Science & R&D

Joint research and technology partnerships
for new drug candidate

Please contact us about research seeds, joint research, assay systems, manufacturing and development, or licensing.